Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD95 ligand in graft rejection.

Literature DB >> 8602212

CD95 ligand in graft rejection.

H Yagita, K Seino, N Kayagaki, K Okumura.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 1996 PMID： 8602212 DOI： 10.1038/379682a0

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors: N P Restifo
Journal: Nat Med Date: 2000-05 Impact factor: 53.440

2. CD95 and CD95L promote and protect cancer stem cells.

Authors: Paolo Ceppi; Abbas Hadji; Frederick J Kohlhapp; Abhinandan Pattanayak; Annika Hau; Xia Liu; Huiping Liu; Andrea E Murmann; Marcus E Peter
Journal: Nat Commun Date: 2014-11-04 Impact factor: 14.919

3. Sources of error in the retracted scientific literature.

Authors: Arturo Casadevall; R Grant Steen; Ferric C Fang
Journal: FASEB J Date: 2014-06-13 Impact factor: 5.191

4. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

Authors: J Allison; H M Georgiou; A Strasser; D L Vaux
Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205

5. Polymorphism of murine Fas ligand that affects the biological activity.

Authors: N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205

6. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.

Authors: M Sata; H Perlman; D A Muruve; M Silver; M Ikebe; T A Libermann; P Oettgen; K Walsh
Journal: Proc Natl Acad Sci U S A Date: 1998-02-03 Impact factor: 11.205

CD95 ligand in graft rejection.

1. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

2. CD95 and CD95L promote and protect cancer stem cells.

3. Sources of error in the retracted scientific literature.

4. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

5. Polymorphism of murine Fas ligand that affects the biological activity.

6. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.

7. Partial tolerance of subcutaneously transplanted xenogeneic tumour cell graft by Fas-mediated immunosuppression.

8. Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

9. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Review 10. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.